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The protozoan parasite Cryptosporidium parvum is
a major cause of gastrointestinal disease; no effec-
tive drug therapy exists to treat this infection. Curi-
ously, C. parvum IMPDH (CpIMPDH) is most closely
related to prokaryotic IMPDHs, suggesting that the
parasite obtained its IMPDH gene via horizontal
transfer. We previously identified inhibitors of
CpIMPDH that do not inhibit human IMPDHs. Here,
we show that these compounds also inhibit IMPDHs
from Helicobacter pylori, Borrelia burgdorferi, and
Streptococcus pyogenes, but not from Escherichia
coli. Residues Ala165 and Tyr358 comprise a struc-
tural motif that defines susceptible enzymes. Impor-
tantly, a second-generation CpIMPDH inhibitor has
bacteriocidal activity on H. pylori but not E. coli. We
propose that CpIMPDH-targeted inhibitors can be
developed into a new class of antibiotics that will
spare some commensal bacteria.
INTRODUCTION
Microbial infections are now the second leading cause of
death worldwide. Many commonly used antibiotics have been
rendered ineffective by the upsurge of drug resistance, and years
of neglect have left amere trickle of newantibiotics in thepipeline,
creating an urgent need for novel scaffolds and targets
(Fischbach and Walsh, 2009). The repurposing of other drug
development programs for antibiotic discovery is a promising
strategy to address this problem (Miller et al., 2009; Walsh and
Fischbach, 2009). Inosine 50-monophosphate dehydrogenase
(IMPDH) presents an intriguing opportunity for such repurposing.
This enzyme catalyzes the pivotal step in guanine nucleotide
biosynthesis, the conversion of IMP to XMPwith the concomitant
reduction of NAD+ in a reaction that involves a covalent interme-
diate E-XMP* (Figure 1A). The guanine nucleotide pool controls
proliferation, so IMPDH inhibitors such as mycophenolic acid,
merimepodib, mizoribine, tiazofurin, and ribavirin are used in
immunosuppressive, cancer, and antiviral therapy. As yet,
IMPDH inhibitors have not been exploited in antimicrobial appli-
cations, in part because no bacterial-selective IMPDH inhibitors
have been identified (Hedstrom, 2009).1084 Chemistry & Biology 17, 1084–1091, October 29, 2010 ª2010 EThe development of IMPDH-based therapy is further compli-
cated by the conformational gymnastics of the catalytic cycle
(Hedstrom, 2009). IMPDHs have two conformational states, an
open conformation that allows NAD to bind, and a closed confor-
mation where a mobile flap binds in the NAD site (Figure 1B)
(Hedstrom, 2009). The closed conformation is required for the
hydrolysis of the covalent intermediate E-XMP*. Thus, the flap
competes with inhibitors that bind in the NAD site, and this
competition is an important determinant of inhibitor potency
(Hedstrom, 2009). For example, Tritrichomonas foetus IMPDH
is 400-fold more resistant to mycophenolic acid than human
IMPDH2; 10-fold of this difference is due to changes in the
structure of the inhibitor binding site while40-fold can be attrib-
uted to a preference for the closed conformation (Digits and
Hedstrom, 2000). Therefore, for TfIMPDH, the conformational
equilibrium is a more important determinant of inhibitor suscep-
tibility than the residues that contact the inhibitor. This example
illustrates the difficulty in predicting inhibitor action from IMPDH
sequence.
The protozoan parasite Cryptosporidium parvum is a major
cause of diarrhea and malnutrition and a potential bioterrorism
agent (Fayer, 2004). The parasite has a streamlined purine
salvage pathway that depends on IMPDH for the production of
guanine nucleotides (Abrahamsen et al., 2004; Striepen et al.,
2004). Surprisingly, CpIMPDH is closely related to prokaryotic
IMPDHs (e.g., Helicobacter pylori IMPDH) (Figure 1C), suggest-
ing that its IMPDH gene was obtained by horizontal transfer
(Striepen et al., 2002, 2004). Prokaryotic and eukaryotic IMPDHs
differ in both structural features and kinetic properties (Zhang
et al., 1999a), which suggests that selective inhibition should
be possible. We have recently identified eight selective inhibitors
of CpIMPDH in a high-throughput screen targeting the NAD site
(compounds A–H) (Table 1) (MacPherson et al., 2010; Maurya
et al., 2009; Umejiego et al., 2008). Several of these inhibitors
display antiparasitic activity in a tissue culture model of
C. parvum infection (Umejiego et al., 2008). A program of medic-
inal chemistry optimization has yielded inhibitors with nanomolar
affinity in several structurally distinct frameworks (MacPherson
et al., 2010; Maurya et al., 2009).
Mycophenolic acid and merimepodib bind in the nicotinamide
subsite of the NAD site of human IMPDH, stacking against the
purine ring of E-XMP* and within a single subunit of the tetramer
(Sintchak et al., 1996; Sintchak and Nimmesgern, 2000).
In contrast, the X-ray crystal structure of inhibitor C64 revealed
that this inhibitor interacts with the purine ring of IMP and thenlsevier Ltd All rights reserved
Figure 1. The IMPDH Reaction
(A) Chemical mechanism: a conserved Cys attacks C2 of IMP and hydride is transferred to NAD+ producing the covalent intermediate E-XMP*. E-XMP* is hydro-
lyzed with a conserved Arg residue acting as a general base to produce XMP.
(B) Phylogenetic tree of IMPDHs.
Constructed as described in Min et al. (2008).
(C) The hydride transfer reaction proceeds in an open enzyme conformation. After NADH departs, a mobile flap folds into the NAD site, carrying the catalytic Arg
into the active site. Inhibitors compete with the flap, so the equilibrium between open and closed states is a determinant of inhibitor affinity.
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cent subunit (Figures 2A and 2B) (CpIMPDH numbering)
(MacPherson et al., 2010). At present, no structures are available
of the other inhibitor complexes. However, with the exception of
compound E, all of the inhibitors contain two aromatic groups
linked by spacers of similar length (Table 1) and therefore may
be able to recapitulate this binding mode.
Here, we demonstrate that Tyr358 together with Ala165
comprise a structural motif that defines susceptibility to all eight
CpIMPDH inhibitors. This motif is found in a wide variety of path-
ogenic bacteria. Importantly, the CpIMPDH inhibitor C91 blocks
H. pylori growth, but not the growth of Escherichia coli. These
observations suggest that CpIMPDH-targeted inhibitors can be
developed into a new class of broader spectrum antibiotics
that will spare commensal bacteria.
RESULTS AND DISCUSSION
Expression, Purification, and Characterization
of Recombinant IMPDHs
We expressed and purified prokaryotic IMPDHs from represen-
tative organisms: H. pylori (Gram-negative 3 proteobacteria),
E. coli (Gram-negative g proteobacteria), B. burgdorferi (spiro-
chete), S. pyogenes (Gram-positive), and the protozoan parasite
T. foetus, which also appears to have obtained its IMPDH gene
from a prokaryote (Bapteste and Philippe, 2002). We also
expressed an additional eukaryotic IMPDH from the protozoan
parasite Leishmania donovani. EcIMPDH, BbIMPDH, TfIMPDH,
SpIMPDH, and LdIMPDH have been characterized previously
(Digits and Hedstrom, 1999; Dobie et al., 2007; Kerr and
Hedstrom, 1997; Zhang et al., 1999b; Zhou et al., 1997). The
kinetic parameters of HpIMPDH are very similar to those of
CpIMPDH, and are generally characteristic of bacterial IMPDHsChemistry & Biology 17, 1084–1(see Table S2 available online) (Hedstrom, 2009; Umejiego et al.,
2004; Zhang et al., 1999a). Importantly, structures are available
for TfIMPDH, SpIMPDH, and BbIMPDH as well as for CpIMPDH
and the human enzymes (Colby et al., 1999; Gan et al., 2002,
2003; MacPherson et al., 2010; McMillan et al., 2000; Prosise
and Luecke, 2003; Prosise et al., 2002; Sintchak et al., 1996;
Whitby et al., 1997; Zhang et al., 1999b). CpIMPDH is most
closely related to HpIMPDH with 60% sequence identity
(Figure 1C; Table S1). The sequence of CpIMPDH is50% iden-
tical to EcIMPDH, BbIMPDH, and SpIMPDH and30% identical
to TfIMPDH and the eukaryotic enzymes (Table S1) (Min et al.,
2008; Striepen et al., 2002). Importantly, HpIMPDH, BbIMPDH,
and SpIMPDH contain Tyr358 and are therefore expected to
be susceptible to the C series inhibitors and perhaps also to
the other CpIMPDH inhibitors.
Spectrum of Inhibition of C Series Inhibitors
Compound C inhibits HpIMPDH and BbIMPDH with similar
values of IC50 to CpIMPDH (Table 1). C is a noncompetitive
(mixed) inhibitor of HpIMPDH with respect to NAD+ (data not
shown), as observed with CpIMPDH (Umejiego et al., 2008).
Importantly, the values of Ki and IC50 are similar, as expected
for noncompetitive inhibition. C also inhibits SpIMPDH, although
in this case the value of IC50 is increased by a factor of 60
relative to CpIMPDH. No inhibition is observed at 100 mM C for
TfIMPDH, EcIMPDH, and LdIMPDH, as expected since these
enzymes do not contain Tyr358.
We also evaluated the spectrum of a second-generation inhib-
itor, C91, arising from our medicinal chemistry optimization
program (S. Kirubakaran, S.K.G., C.R. Johnson, M. Zhang,
D.R.G., L.H., and G.D. Cuny, unpublished data); this compound
is a potent inhibitor of CpIMPDH with IC50 = 8 nM. C91 is also
a potent inhibitor of both HpIMPDH and SpIMPDH,091, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1085
Table 1. Inhibition of IMPDHs by Compounds A–H
Compound
IC50 (mM)
CpIMPDHa HpIMPDH BbIMPDH SpIMPDH EcIMPDH- S250A/L444Y
A
ClHN
O
O
3.3
0.66
2.2
1.1
1.4
0.84
96
12
1.8
0.54
B
H
N
O O
1.6
0.32
1.3
0.65
1.8
1.1
85
11
0.70
0.21
C
HN
O
N
N
S
N
O
1.2
0.24
0.60
0.30
0.60
0.36
70
9.1
0.60
0.18
D
N
N
O
H
N
O
O
5.4
1.1
3.0
1.5
1.7
1.0
49
6.4
2.3
0.69
E
N
H
O
O
O
1.6
0.32
1.5
0.75
0.90
0.54
15
2.0
1.8
0.54
F
S
N
N
O
S O
HN O
1.4
0.28
1.1
0.55
0.80
0.48
13
1.7
1.1
0.33
G
H
N
N
O
O
NH2
0.1
0.02
0.30
0.15
0.22
0.13
0.55
0.07
0.40
0.12
H
H
N
N
O
O
NH2
0.9
0.18
1.2
0.6
0.90
0.54
0.86
0.11
1.0
0.3
C91
H
N
O
NN
N
0.008b,c
0.0016
0.0011b,d
0.0005
n.d. 0.0054b,c
0.0007
0.0019b,e
0.0006
These compounds (100 mM) do not inhibit EcIMPDH, TfIMPDH, and LdIMPDH. The errors on the IC50 values were less than 10% unless otherwise
noted. ‘‘Intrinsic’’ values (adjusted for the fraction of enzyme in the open conformation) are shown in italics. Supported by Figure S1.
a Data from Umejiego et al. (2008).
b Determined with a tight-binding equation.
c Error%37%.
d Error = 73%;
e Error = 52%.
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Figure 2. Structures of IMPDH Inhibitor
Binding Sites
(A) Structure of C64.
(B) Structure of the CpIMPDH,IMP,C64 complex
(salmon; PDB accession 3KHJ) (MacPherson
et al., 2010) and resistant IMPDHs from T. foetus
(green; 1LRT) (Gan et al., 2002) and Chinese
hamster (blue; 1JR1, nearly identical to human
IMPDH2) (Sintchak et al., 1996). Residues within
5 A˚ of C64 are displayed. C64 is shown in gray
with a transparent surface; CpIMPDH residues
are labeled; residue from the adjacent mono-
mer are denoted with an apostrophe. Residues
Thr221 and Glu329 are hidden under C64.
(C) The surface of the NAD binding site rendered
by conservation of residues in prokaryotic
IMPDHs from T. foetus, C. parvum, H. pylori, B.
burgdorferi, S. pyogenes, and E. coli. Dark
magenta, 100% conserved; tan, 63%; dark cyan,
25%. The NAD analog tiazofurin adenine dinucle-
otide (TAD) is light gray. The tiazofurin binding
site is circled in blue and the ADP binding site is
circled in red.
(D) The surface of theC64 binding site rendered by
conservation of residues in sensitive IMPDHs from
C. parvum, H. pylori, and B. burgdorferi, as well as
the S250A/L444Y variant of EcIMPDH. Ser164,
Met326, and Ser354 are within 5 A˚ of C64;
Val143 is 8 A˚ away. Dark magenta, 100%
conserved; tan, 60%; dark cyan, 20%. C64 de-
picted in ball-and-stick in light gray and IMP is
shown in stick in dark gray.
(E) The surface of the C64 binding site rendered by conservation of residues in CpIMPDH and IMPDHs from 19 pathogenic bacteria: Acinetobacter baumannii
(wound infection), Bacillus anthracis (anthrax), Bacteroides fragilis (peritoneal infections), Brucella abortus/melitensis/suis (brucellosis), B. burgdorferi (Lyme
disease), Burkholderia cenocepacia (infection in cystic fibrosis), Bu. mallei (glanders), Bu. pseudomallei (melioidosis), Campylobacter jejuni (food poisoning),
C. lari (food poisoning), Coxiella burnetii (Q fever), Francisella tularensis (tularemia), H. pylori (gastric ulcer/stomach cancer), Listeria monocytogenes (listeriosis),
Staphylococcus aureus (major cause of nosocomial infection), S. pyogenes (major cause of nosocomial infections), and S. pneumoniae (pneumonia). Dark
magenta, 100% conserved; tan, 63%; dark cyan, 25%. Alignments were constructed with CLUSTALW2 and molecular graphics images were produced using
the UCSF Chimera package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIH
P41 RR-01081) (Pettersen et al., 2004).
Supported by Figure S3.
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obtained (Table 1). C91 fails to inhibit EcIMPDH, TfIMPDH,
LdIMPDH or human IMPDHs (IC50 > 10 mM).
The Conformational Contribution to Inhibitor Selectivity
As noted in the introduction, IMPDH undergoes a conformational
change in the middle of its catalytic cycle that brings a mobile
flap into the NAD site (Figure 1B). The competition of the flap
for this site can be an important determinant of inhibitor suscep-
tibility and might explain the low susceptibility of SpIMPDH to C
despite the presence of Tyr358 (Table 2; Guille´n Schlippe and
Hedstrom, 2005a, 2005b; Guille´n Schlippe et al., 2004;
Hedstrom, 2009; Kohler et al., 2005; Riera et al., 2008; Umejiego
et al., 2004). Therefore, we determined the equilibrium between
open and closed conformations (Kc) for the various IMPDHs
(Table 2) Figure S3 and Supplemental Experimental Procedures
for description) (Hedstrom, 2009). The values of Kc vary consid-
erably among the prokaryotic IMPDHs, from 0.7 for BbIMPDH to
140 for TfIMPDH.
Tiazofurin inhibition illustrates the validity of this approach and
the magnitude of the conformational contribution to inhibitor
selectivity. The tiazofurin binding site is conserved amongChemistry & Biology 17, 1084–1prokaryotic IMPDHs (Figure 2C), which predicts that CpIMPDH,
HpIMPDH, BbIMPDH, SpIMPDH, EcIMPDH, and TfIMPDH
should all bind tiazofurin with similar affinity, yet the measured
values of Ki vary from 1 to 69 mM. When the measured values
of Ki are adjusted for competition from the mobile flap, that is,
by dividing by a factor of 1 + Kc to normalize for the fraction of
protein in the open conformation, the resulting ‘‘intrinsic’’ values
are indeed nearly identical, ranging from 0.3 to 0.7 mM (Table 2).
In contrast, the intrinsic values of Ki for ADP range from 0.2 to
9 mM, reflecting the structural divergence of the ADP binding
sites among the six enzymes (Figure 2C). Therefore, the intrinsic
values reflect the structural similarity of the inhibitor binding
sites.
The intrinsic values of IC50 for C are similar for CpIMPDH,
HpIMPDH, and BbIMPDH, indicating that the structures of inhib-
itor binding sites are also similar in these three enzymes.
However, the intrinsic value of IC50 for C with SpIMPDH remains
40-fold greater than CpIMPDH. Figure 2 displays the conserva-
tion of the C64 binding site among these IMPDHs. While most
of the residues within 5 A˚ of C64 are conserved among these
enzymes, Ser164 and Met326 are variable; these residues are
Thr and Leu, respectively, in SpIMPDH. Perhaps these091, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1087
Table 2. The Conformational Contribution to Potency of IMPDH
Inhibitors
Enzyme
Ki Tzf
(mM)
Ki ADP
(mM) Kc
Kint Tzf
(mM)
Kint ADP
(mM)
CpIMPDHa 1.5 ± 0.1 42 ± 6 4 0.3 8
HpIMPDH 1.3 ± 0.1 6.0 ± 0.5 1 0.7 3
BbIMPDH 1.1 ± 0.2 7.4 ± 0.6 0.7 0.7 4
SpIMPDH 8 ± 1 13 ± 2 7 0.7 2
TfIMPDHa 69 ± 9 31 ± 2 140 0.5 0.2
EcIMPDH 5.3 ± 0.6 10 ± 2 9 0.5 1
EcIMPDH-
S250A
2.5 ± 0.3 0.10 ± 0.01 1.5 1 0.04
EcIMPDH-
S250A/L444Y
1.1 ± 0.2 4.1 ± 0.7 2.3 0.3 1
hIMPDH2a 1.3 ± 0.1 9 ± 2 %0.2 1.3 9
LdIMPDH 8.3 ± 0.7 15 ± 2 2.3 2.5 5
As shown in Figure 1B, inhibitors compete with the mobile flap for the
vacant NADH site. Therefore the observed affinity will be determined by
the intrinsic affinity of the inhibitor for the NAD site and the affinity of
the flap, i.e., Kint = Ki /(1 + Kc), where Kint is the intrinsic affinity, Ki is the
measured inhibition constant and Kc is the conformational equilibrium
determined as described in Experimental Procedures. Supported by
Figure S2.
a Data from Riera et al. (2008).
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In contrast, the intrinsic values of IC50 for C91 are similar for
CpIMPDH,HpIMPDH, and SpIMPDH, indicating that the interac-
tions that increase the potency of C91 in CpIMPDH are also
found in the other enzymes.
Structural Determinants of C Susceptibility
To determine if the presence of Tyr358 is sufficient to install
sensitivity to inhibitor C, we replaced the corresponding residue
in EcIMPDH with Tyr. The resulting variant, L444Y, has similar
kinetic properties to EcIMPDH, except that the value of Km for
NAD+ is increased by 5-fold (Table S2). Unlike EcIMPDH,
C inhibits L444Y (Figure S2); however, L444Y is still 100-fold
less sensitive than CpIMPDH.
Inspection of the residues within 5 A˚ of C64 revealed another
potential structural determinant of C susceptibility: Ala165
(Figure 2A). The installation of Ala at the corresponding position
of EcIMPDH also increased the sensitivity to C, although again
the resulting variant, S250A, is 100-fold less sensitive than
CpIMPDH (Figure S2). However, the combination of these muta-
tions created a variant S250A/L444Y with similar sensitivity to
C asCpIMPDH (Table 1). The S250A/L444Y variant also displays
similar sensitivity to C91 (Table 1). Therefore, Ala250 and Tyr358
comprise a minimal structural motif that defines sensitivity to C.
All of the CpIMPDH Inhibitors Interact with Ala165
and Tyr358
The spectra of inhibition of compounds A, B, and D–H are also
very similar to C. These seven compounds inhibit HpIMPDH,
BbIMPDH, and SpIMPDH, but not EcIMPDH, TfIMPDH, or
LdIMPDH (Table 1). These compounds are noncompetitive
(mixed) inhibitors of HpIMPDH with respect to NAD+ (data not1088 Chemistry & Biology 17, 1084–1091, October 29, 2010 ª2010 Eshown), as observed with CpIMPDH (Umejiego et al., 2008).
Most importantly, the EcIMPDH variant S250A/L444Y is in-
hibited by A, B, and D–H, indicating that together Ala165 and
Tyr358 define the structural motif required for susceptibility to
all the CpIMPDH inhibitors. Note that compound E has a single
aromatic group and therefore must interact exclusively with
Tyr358 and not with the purine ring of IMP.
Two Inhibitor Binding Modes Exist
Although the above observations indicate that all of the
compounds interact with Ala165 and Tyr358, inspection of the
intrinsic values of IC50 for all of the CpIMPDH inhibitors reveals
two distinct binding modes. The intrinsic values of IC50 of C
range between 0.18 and 0.36 mM for CpIMPDH, HpIMPDH,
BbIMPDH, and S250A/L444Y (Table 2), reflecting the conserva-
tion of this binding site (Figure 2D) (MacPherson et al., 2010).
Likewise, the intrinsic affinities of compounds A, B, D, E, and F
are within a factor of 2 for all four enzymes, indicating that the
binding sites of these compounds are also conserved. In
contrast, the intrinsic values of A–F for SpIMPDH are very
different fromCpIMDPH, indicating that this binding site is signif-
icantly different in SpIMPDH (Table 1). Only one substitution is
present within 3.5 A˚ of C64: Met326 is a Leu in SpIMPDH.
However, the Leu substitution is also present in HpIMPDH and
BbIMPDH and therefore cannot account for the different suscep-
tibility. The next nearest substitution is Thr for Ser164; the side
chain of Ser164 is 5 A˚ away from C64, but might be closer to
A, B, and D–F.
A different trend is observed in the intrinsic affinities of G
and H. SpIMPDH is most similar to CpIMPDH, while HpIMPDH
and BbIMPDH display lower affinities for these compounds
(Table 2). These observations suggest that G/H bind in a region
that is conserved in SpIMPDH andCpIMPDH, but different in the
other enzymes. Therefore, at least a portion of the G/H binding
site must be distinct from the site that binds A–F. Figure S3
reveals regions of conservation between CpIMPDH and
SpIMPDH that are not shared with the other sensitive enzymes.
These regions could serve as the binding site for G/H.
Inhibition of H. pylori Growth
We chose to investigate the antibiotic potential of IMPDH inhibi-
tion in H. pylori because HpIMPDH is most similar to CpIMPDH.
H. pylori causes gastrointestinal ulcers and stomach cancer;
standard treatment involves triple therapy of a proton pump
inhibitor, clarithromycin, and amoxicillin or metronidazole
(Selgrad andMalfertheiner, 2008).Moreover, resistance is devel-
oping to the standard triple therapy, and few new antibiotics are
in the pipeline. H. pylori has complex growth requirements that
necessitate the use of rich media containing xanthine and
guanine (Brucella broth) (Tomb et al., 1997). H. pylori will be
resistant to IMPDH inhibitors if its salvage pathways can provide
sufficient guanine nucleotides to support proliferation. There-
fore, this bacteria provides a demanding test for the antibiotic
potential of IMPDH-targeted inhibitors.
Figure 3 shows that 20 mM C91 is sufficient to block the prolif-
eration of a H. pylori culture exiting stationary phase. Higher
concentrations of C91 display bactericidal effects, with only
23% of the colony forming units remaining after 24 hr treatment
with 200 mM. Exponentially growing H. pylori cells are alsolsevier Ltd All rights reserved
Figure 3. C91 Inhibits H. pylori Growth
(A) CompoundC91 in DMSO was added to freshly
diluted stationary cultures of H. pylori strain G27 in
Brucella broth. Samples were removed at the indi-
cated time points, diluted, and plated to determine
bacterial proliferation/survival. Each point is the
averageof duplicate determinations; a representa-
tive of three experiments is shown. Black, DMSO
alone. C91 concentrations: purple, 2 mM; blue,
7 mM; green, 20 mM; orange, 60 mM; red, 200 mM.
(B) Compound C91 was added to freshly diluted
cultures of E. coli MG1655 in Luria broth. Each
point is the average of three determinations; the
standard deviations are smaller than the point.
Black, DMSO alone. C91 concentrations: orange,
100 mM; red, 200 mM.
Supported by Figure S4.
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to block growth while higher concentrations are bactericidal.
Importantly,C91 failed to inhibit the growth of E. coli, suggesting
that the antibacterial effects of C91 result from the inhibition of
HpIMPDH rather than an off-target effect.
Implications for the Design of Antibiotics Targeting
IMPDH
The above findings indicate that Ala165 and Tyr358 comprise
a structural motif that defines enzymes susceptible to CpIMPDH
inhibitors. A BLAST search reveals that these critical residues are
present in IMPDHs from a wide variety of pathogenic bacteria in
addition to C. parvum, B. burgdorferi, H. pylori and S. pyogenes.
Importantly, this list includes select agents and multidrug resis-
tant bacteria, where new antibiotics are urgently needed, but
not E. coli (Table S1). As shown in Figure 2E, the inhibitor binding
site is highly conserved among C. parvum and pathogenic
bacteria, suggesting that IMPDH inhibition provides a promising
strategy for the development of a broader spectrum antibiotic.
Prokaryotic-specific inhibitors such as C91 will be invaluable in
validating IMPDH as a target for antibiotic chemotherapy that
will spare commensal bacteria.
SIGNIFICANCE
The rising tide of antibiotic resistance creates an urgent
need for new drugs to treat bacterial infections, but years
of neglect have depleted the antibiotic pipeline. The repur-
posing of other drug development programs for antibiotic
discovery is a promising strategy to address this problem.
Inosine 50-monophosphate dehydrogenase (IMPDH), a key
enzyme in the biosynthesis of the precursors for RNA and
DNA, presents an intriguing opportunity for such repurpos-
ing. IMPDH is a promising target for drugs against the proto-
zoan parasite Cryptosporidium parvum, a major cause of
diarrhea andmalnutrition and a potential bioterrorism agent.
Curiously, CpIMPDH is most closely related to prokaryotic
IMPDHs, suggesting that the parasite obtained its IMPDH
gene via horizontal transfer. We previously identified inhibi-
tors ofCpIMPDH that do not inhibit human IMPDHs. Here we
show that selective inhibitors of CpIMPDH also inhibit
IMPDHs from the pathogenic bacteria Helicobacter pylori,Chemistry & Biology 17, 1084–1Borrelia burgdorferi, and Streptococcus pyogenes, but
not Escherchia coli. Importantly, a second-generation
CpIMPDH inhibitor blocks H. pylori growth, demonstrating
that these compounds have antibacterial activity. Suscep-
tible enzymes are defined by a structural motif that is found
in IMPDHs from a wide variety of pathogenic bacteria, sug-
gesting that IMPDH-targeted inhibitors can be developed
into a new class of broader spectrum antibiotics that will
spare some commensal bacteria.
EXPERIMENTAL PROCEDURES
Materials
Compounds D, E, F,G, and Hwere purchased from ChemDiv Inc. (San Diego,
CA), CompoundsA,B, andCwere synthesized as described previously (Ume-
jiego et al., 2008). Compound C91 was synthesized as described in Supple-
mental Experimental Procedures. All other chemicals were obtained from
Fisher Scientific, unless mentioned otherwise. Plasmid containing the guaB
gene of S. pyogenes was a generous gift of Dr. Cameron Ashbaugh
(Ashbaugh and Wessels, 1995). H. pylori total genomic DNA was obtained
from American Type Culture Collection (ATCC). L. donovani IMPDH coding
sequence was the gift of Dr. Buddy Ullman (Wilson et al., 1991).
Enzyme Cloning and Purification
Recombinant T. foetus, B. burgdorferi, E. coli and C. parvum IMPDH were
expressed in DguaB strains of E. coli (which lack endogenous IMPDH) and
purified as described previously (Digits and Hedstrom, 1999; Kerr and Hed-
strom, 1997; Umejiego et al., 2004; Zhou et al., 1997). The S250A, L444Y,
and S250A/L444Y mutants of E. coli IMPDH were constructed using Quik-
change (Stratagene, La Jolla, CA). Enzymes were expressed and purified as
previously described (Kerr and Hedstrom, 1997).
To express L. donovani IMPDH, a NcoI site was created at the beginning of
the LdIMPDH coding sequence and the NcoI-PstI fragment was cloned into
pKK233-2 to create the plasmid pLDI, which expresses LdIMPDH under
control of the trc promoter. Cultures were induced with 0.5 mM IPTG and
grown overnight. Cells were harvested by centrifugation, resuspended in
50mMTris-HCl (pH 8.0), 1mMdithiothreitol, and 10%glycerol (Buffer A), lysed
by sonication and clarified by centrifugation followed by filtration through
a 45 mm cellulose acetate filter. Protein was applied to a Poros HS strong
cation exchange resin (PerSeptive Biosystems) pre-equilibrated with 20 mM
sodium phosphate buffer (pH 7.5), 1 mM dithiothreitol (Buffer B). LdIMPDH
was eluted with a gradient of 0–0.9 M NaCl. Fractions containing IMPDH
activity were pooled and applied to IMP affinity resin. The column was washed
with Buffer B and enzymewas eluted with Buffer B containing 0.5 MKCl, 1 mM
IMP. The specific activity of the final preparation was 2.6 mmol/min-mg.
The H. pylori and S. pyogenes guaB genes were cloned into pET28a with 6x
His-tags. Bacteria were grown at 30C in LB medium containing 25 mg/ml091, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1089
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ated by the addition of 0.5 mM IPTG and the temperature was changed to
25C. Bacteria were harvested after 16 hr. The cell pellet was rinsed (3x)
with 50 mM phosphate buffer, 500 mM NaCl, 5 mM imidazole (pH 8.0),
1 mM IMP, and 5 mM b-mercaptoethanol, and lysed by sonication. The lysate
was clarified by centrifugation and loaded on a Ni-NTA column (QIAGEN). The
purified protein were eluted in 50 mM phosphate buffer, 500 mM NaCl,
250mM imidazole (pH 8.0), 1 mM IMP, and 5mM b-mercaptoethanol, concen-
trated, and dialyzed against Buffer A. The protein concentration was deter-
mined by using Bradford dye procedure (Bio-Rad).
Steady-State Enzyme Kinetics
IMPDH assays were performed in 50mM Tris-HCl (pH 8.0), 100mMKCl, 3 mM
EDTA, and 1 mMDTT. Activity was routinely assayed in the presence of 50 nM
IMPDH at 25C. NADH production was monitored either by following absor-
bance change at 340 nm using a Hitachi U-2000 spectrophotometer
(3 = 6.2 mM1 cm1). IMPDHs are prone to NAD+ substrate inhibition (Hed-
strom, 2009). Therefore, the steady-state kinetics for HpIMPDH were initially
analyzed by varying NAD+ at saturating IMP concentrations to determine the
value of Km for NAD
+, then by varying IMP at the fixed NAD+ concentration as
close to saturating as practical. Using the SigmaPlot program (SPSS, Inc.),
initial velocity data were fit to the Michaelis-Menten equation (Equation 1)
and/or the uncompetitive substrate inhibition equation (Equation 2), as follows:
n=Vm½S=ðKm + ½SÞ (1)
n=Vm=

1+Km=½S+ ½S2=Kii

; (2)
where v represents the velocity, Vm is the maximal velocity, S is the substrate
concentration, Km is the Michaelis constant, Kii is the intercept inhibition
constant. The values of kcat determined under both conditions are in good
agreement.
Inhibitor Kinetics
Enzyme was incubated with inhibitor (50 pM to 100 mM) for 10 min at room
temperature prior to addition of substrates. The conditions used for each
enzyme is listed in Supplemental Experimental Procedures. IC50 values were
calculated for each inhibitor according to Equation 3 using the SigmaPlot
program (SPSS, Inc.):
yi = y0=ð1+ ½I=IC50Þ; (3)
where yi is initial velocity in the presence of inhibitor (I) and y0 is the initial
velocity in the absence of inhibitor.
Assays were carried out in assay buffer at 25C with 50 nM IMPDH and
NADH production was monitored by following fluorescence. The values of Ki
with respect to NAD+ were determined by using fixed concentrations of IMP
and varied NAD+ concentrations. Data were fitted according to Equation 4
(noncompetitive inhibition) using SigmaPlot program (SPSS, Inc.):
y=Vm½S=fKmð1+ ½I=KisÞ+ ½Sð1+ ½I=KiiÞg; (4)
where Kii and Kis represent the intercept and slope inhibition constants,
respectively. The best fits were determined by the relative fit error. The Morri-
son equation was used to evaluate tight-binding inhibitors (Morrison, 1969).
Determination of Kc
The values of Kc were determined bymeasuring the interaction between tiazo-
furin and ADP (Digits and Hedstrom, 2000; Hedstrom andWang, 1990). Tiazo-
furin binds in the nicotinamide subsite of the NAD site while ADP binds in the
adenosine subsite. If the closed conformation is favored, tiazofurin and ADP
will interact synergistically; one inhibitor shifts the enzyme into the open
conformation and promotes the association of the second inhibitor (Guille´n
Schlippe et al., 2004). If the open conformation is favored, the two inhibitors
bind independently. Tiazofurin and ADP concentrations are varied at constant
IMP and NAD+. Initial velocities were fit to Equation 5 using SigmaPlot:
n= n0=½1+ ½I=Ki + ½J=Kj + ½I½J=aKiKj; (5)
where n is the initial velocity, n0 is the initial velocity in the absence of inhibitor,
Ki and Kj are the inhibition constants for the inhibitors I and J, respectively, and1090 Chemistry & Biology 17, 1084–1091, October 29, 2010 ª2010 Ea is the interaction constant. The value of a approximates the fraction of
enzyme in the open conformation, so the value of Kc is obtained (Guille´n
Schlippe et al., 2004):
Kc = ð1 aÞ=a: (6)
Bacterial Growth Assays
H. pylori strain G27 (Baltrus et al., 2009) was stored at80C in Brucella broth
(Becton Dickinson) supplementedwith 10% fetal bovine serum (FBS) and 20%
glycerol. Bacteria were plated on TSA/sheep blood agar plates (Remel) or
grown in growth media (Brucella broth supplemented with 10% FBS and
4 mg/ml fungizone/amphotericin B) at 37C in a 10%CO2 incubator. For growth
inhibition assays, a frozen stock of H. pylori strain G27 was plated on blood
agar plates and allowed to grow for 48 hr. The bacteria were resuspended in
growth media (30 ml) and incubated for 18–20 hr. The resulting stationary
phase bacteria were diluted into assay media (Brucella broth with 10% FBS)
to an OD600 = 0.025 (104 colony forming units/ml) and aliquots (200 ml) were
added to 96-well tissue-culture grade polystyrene plates (Costar, Corning
Inc.). A DMSO solution of C91 (2 ml) was added to each well and the plates
were incubated with shaking. Colony forming units (CFUs) were measured
by diluting aliquots at 0, 2, 4, 8, 12, and 24 hr, and plating on blood agar plates.
Alternatively, logarithmic phase bacteria were obtained by diluting stationary
phase bacteria 5x into fresh growth media (25 ml) and incubating with shaking
for 4 hr prior to the growth inhibition assay.
An exponentially growing culture of E. coli MG1655 was diluted into fresh
Luria broth containing C91 (100 and 200 mM) or DMSO. The triplicate cultures
were incubated at 37C in a plate reader and optical density was recorded
every minute over 3.5 hr.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and two tables and can be found with this article online at
doi:10.1016/j.chembiol.2010.07.014.
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